All News

Since the adoption of the Affordable Care Act, CMS has removed 28,000 questionable providers from Medicare. But the Government Accountability Office found more needs to be done to verify addresses and weed out those who have lost their licenses.

Zarxio (filgrastim-sndz), manufactured by Sandoz as a biosimilar to Amgen's Neupogen, has finally received marketing approval from a federal appeals court.

More than half of patients in numerous disease states are nonadherent to their medications and 30% of patients do not fill their prescriptions.

Merck (MSD) has announced that its PD-1 inhibitor pembrolizumab (Keytruda) was approved by the European Commission for the treatment of advanced (unresectable or metastatic) melanoma in adults.

A new program from the Institute for Clinical and Economic Review will produce public reports that include a full analysis of the comparative effectiveness, the cost-effectiveness, and the potential budget impact of new drugs.

The study, published in the Annals of Internal Medicine, examined antibiotic prescribing pratices within the Department of Veterans Affairs.

The results will not wipe out a recent $2.37 billion settlement reached in about 9000 bladder cancer claims involving the drug.

The new law was part of a 21-bill package to fight one of the nation's highest rates of opioid and heroin abuse.

Researchers at UCLA have discovered that inhibiting SGLT2 in pancreatic and prostate adenocarcinomas can reduce cancer cell survival.

The American Society of Clinical Oncology has issued a position statement in the Journal of Clinical Oncology, calling for federal agencies and the cancer research community to broaden clinical trials to include older adults.

Instead of making patients suffering from life-limiting illnesses choose between hospice care and curative care, CMS will test coverage that allows individuals to receive palliative and curative treatment concurrently.

In the first clinical study to demonstrate the importance of precision medicine in lymphomas, researchers determined that patients with a specific molecular subtype of diffuse large B-cell lymphoma responded better to ibrutinib than patients with a different molecular subtype.

The Exchange Pulse Report published by Express Scripts predicts that compared with 2014, the year 2015 will see a greater number of younger enrollees signing up on healthcare exchanges, which could potentially drive down drug costs for specialty medications.

In a pattern repeated among those who gained insurance on the Marketplace exchanges, it's clear the uninsured had more pent-up medical needs than policymakers realized.

Nivolumab proved superior to everolimus in improving overall survival in previously treated patients.

A new blog post at RAND argues that Medicare's plans to reimburse providers for advance care planning has been a long time coming.

A gene known to cause cancer may also play a role in determining obesity, according to researchers at the Virginia Commonwealth University Massey Cancer Center.

The top story was Marilyn Tavenner became the nation's top healthcare lobbyist when she was named the new president and CEO of America's Health Insurance Plans, plus the controversial new guidelines that called for more Americans to take statins were validated, according to the results of a new study.

Hackers have accessed the personal information of 4.5 million people after the UCLA Health System became the victim of a cyberattack on May 5, 2015.

Long-term acute care hospitals provide better outcomes and more cost-effective care when treating critically ill and medically complex patients.

Approximately 9 million Medicare beneficiaries are considered "complex care" and they often incur high out-of-pocket costs. As lifespans lengthen, it becomes important for Medicare to adapt to serve these complex care beneficiaries.

The demand for oral parity for oncology medications is back up for vote in the Senate in North Carolina.

Nearly 50 years after President Johnson signed the law that created them, Medicare and Medicaid have become part of the fabric of the US healthcare system. A Kaiser Family Foundation poll finds little support for proposals to alter the basic structure of the programs.

A report released by the healthcare research group Avalere Health claims that health insurance exchanges have a significantly narrow network compared with their commercial counterparts.

The Annual Report to the Nation on Status of Cancer, product of a collaboration between The American Cancer Society, Centers for Disease Control and Prevention, National Cancer Institute, and North American Association of Central Cancer Registries, has been published.

As Amgen's Repatha (evolocumab) and Sanofi/Regeneron's Praluent (alirocumab) get closer to market, the safety question is one of the remaining pieces of the puzzle that unfortunately can't be solved immediately until real-world data starts to become available. However, as payers assess the risk-benefit of Repatha and Praluent vs the gold standard statins, there are questions that CAN be answered immediately.

Viruses, not bacteria, are the most commonly detected pathogen in US adults hospitalized with pneumonia; however, neither viruses nor bacteria were detected in the majority of these patients despite current diagnostic tests.

A study published in JAMA Oncology questions aggressive local treatment strategies in men with low-risk prostate cancer.

The Government Accountability Office received notices of inconsistent information, but it wasn't enough for CMS to cancel coverage for the phony beneficiaries. A key flaw revealed is the ability of phony applicants to use the telephone to bypass online controls.

Although Hispanic adults were more likely to have a consistent place of care in 2014 compared with 2013, they were still more likely to experience difficulty in accessing and utilizing care than the non-Hispanic population.